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OBJECTIVES: Chemotherapy-induced nausea and vomiting
(CINV) remains a major adverse effect of cancer therapy. We
aimed to determine outcomes and cost-effectiveness associated
with use of aprepitant in patients undergoing cisplatin based
chemotherapy in Hungary from a patient’s and payer’s perspec-
tive. METHODS: A global decision-analytic model was adapted
in Hungary which compared an aprepitant regimen (aprepitant/
ondansetron/dexamethasone) to a control regimen (ondansetron/
dexamethasone) over a ﬁve days period. Clinical results observed
in aprepitant phase III clinical trials, and utility data came from
published literature were assingned Hungarian resource utilisa-
tion and unit cost data. RESULTS: Complete responders over
one chemotherapy cycle was observed in 71.9% of patients in the
aprepitant group compared to 59.9% of patients in the control
group. Total cost per patient in aprepitant and control group was
€259 and €254 restrospectively. As the result of cost-effectiveness
analyses was practically cost neutral; the incremental cost per
additional responder was irrelevant (€5). Patients were estimated
to have gained an equivalent of 8,25 additional hour of perfect
health per three cycle (0,34 quality-adjusted life days) with
aprepitant-based regimen compared to control regimen. Cost per
quality-adjusted life year gained with aprepitant was estimated at
€5363. CONCLUSIONS: Aprepitant-based strategy is more
effective in CINV-related health outcomes in patients undergoing
highly emetogenic chemotherapy. Incremental beneﬁts materia-
lised in a cost-effective fashion.
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OBJECTIVES: Bisphosphonates have been shown to be effective
in reducing the incidence of skeletal-related events (SREs) in
patients with metastatic bone disease (MBD) originated from any
type of malignancy. The purpose of this study was to evaluate the
cost-effectiveness of clodronate and zoledronate in the preven-
tion of SREs in patients with MBD METHODS: A Markov
model was developed to represent a cohort of patients diagnosed
with MBD. The model had four primary health states: “without
SRE”, “with SRE (i.e., pathologic fracture, radiotherapy or
surgery, and hypercalcemia”), “osteonecrosis” and “death”.
Patients evaluated were those diagnosed with MBD, presenting
any SRE and treated with clodronate or zoledronate. Transition
probabilities originated from a meta-analysis previously pub-
lished by our group. Time-horizon used was ﬁve years. Cost data
were obtained from national privately-administered databases.
Outcomes evaluated were costs, quality-adjusted life years
(QALYs), and SRE-free years. Univariate and multivariate sensi-
bility analyses were used to determine model robustness. Costs
were reported in 2007 Brazilian Reais (1R$ = 1.60US$)
RESULTS: MBD treatment total cost in Brazil (on average, per-
patient) in ﬁve years (base-case) was R$49,004 with clodronate
and R$53,076 with zoledronate. For both drugs, drug cost drove
the overall cost of MBD management (>90%). Clodronate and
zoledronate generated (on average, per-patient) 2.00 and 1.90
QALYs (5-year time-horizon), respectively. Within the same
time-horizon, clodronate and zoledronate also generated (on
average, per-patient) 1.81 and 1.76 SRE free-years, respectively.
When clodronate and zolendronate were contrasted for cost-
effectiveness, clodronate was considered dominant. Multivariate
sensitivity analysis did not show changes in original results
CONCLUSIONS: Clodronate was dominant (i.e., produced
higher effectiveness and lower costs) in comparison to zoledr-
onate for preventing SREs in patients diagnosed with MBD in
Brazil from the private sector perspective.
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OBJECTIVES: to conduct a cost-effectiveness analysis compar-
ing chemoradiotherapy with cisplatine and radiotherapy alone,
to treat inoperative advanced head and neck cancer. METHODS:
we collected data from 29 patients in a prospective study on
chemoradiotherapy with cisplatine, conducted at Hospital das
Clínicas—HC-FMUSP,(strategy 2). For strategy 1, we collected
retrospective data of 33 patients treated with radiotherapy at
HC-FMUSP and Hospital A.C. Camargo. We considered only
direct costs (personnel, drugs, material and equipment deprecia-
tion). We considered, the National Health Service(SUS) reim-
bursement parameters as the payer’s, and HC-FMUSP costs as
the institutional perspectives. The time horizon was 13 months.
We measured effectiveness as years of disease-free life gained. We
collected costs and effectiveness data and calculated the cost-
effectiveness incremental ratio—RICE, which expresses addi-
tional costs per life year gained, in strategy 2, compared to
strategy 1, the standard treatment. RESULTS: A total of 24.13%
of the patients treated in strategy 1 lived more than 12 months,
without disease progression, compared to 48.48% of the patients
in strategy 2,. According to the payer’s perspective, the total cost
per patient in strategy one is US$1,742.01 (1 US dollar equals
1,60 Reais) and US$ 3090,00 in strategy 2. Considering the
institutional perspective, total costs are US$1,762.59, and
US$3,661.50 respectively. In the payer’s perspective, the cost-
effectiveness incremental ratio of strategy 2 compared to 1 is
US$55.40 dollars per life’s year gained. In the institutional per-
spective, RICE is US$77.98. We conducted a one way sensitivity
analysis to verify our calculations. CONCLUSIONS: Chemora-
dioterapy with cisplatin proved more cost-effective than radio-
therapy. There are no Brazilian guidelines about payment for
additional life years. The World Bank guidelines considers the
countries’ GDP per capita an acceptable cost per additional year
of life. Given Brazil’s GDP per capita (US$6080.51 in 2004), the
incremental cost of both is acceptable.
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OBJECTIVES: To perform an economic evaluation of First-line
mCRC treatment with Irinotecan based schemes. (FOLFIRI) +
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